Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05485909 Recruiting - Clinical trials for Colorectal Cancer Liver Metastases

Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

Start date: July 25, 2022
Phase: Phase 2
Study type: Interventional

The incidence of colorectal cancer liver metastasis is high and the prognosis is poor. Improving the treatment effect of colorectal cancer liver metastasis is the key to improving the prognosis of colorectal cancer patients. Rigofenib is one of the standard third-line treatments for advanced colorectal cancer, but has limited efficacy. Immune checkpoint inhibitors (PD-L1 monoclonal antibody, PD-1 monoclonal antibody) have achieved good results in the treatment of various malignant tumors. In a mouse transplant tumor model of colorectal cancer, regorafenib combined with PD-1 monoclonal antibody treatment significantly improved the antitumor activity, but the efficacy rate in clinical studies was not very high, especially for liver metastases. Radiofrequency ablation (RFA) is one of the common methods for the treatment of liver metastases. RFA may improve the immune microenvironment and the efficacy of immunotherapy,and the purpose of this trial is to explore the efficacy and safety of rigofenib and terepliumab combined with RFA in patients with refractory colorectal cancer liver metastasis.

NCT ID: NCT05485077 Recruiting - Colorectal Cancer Clinical Trials

A Prospective Cohort Study on Colorectal Cancer Screening in Community Population

Start date: July 9, 2022
Study type: Observational

This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. In this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.

NCT ID: NCT05482529 Recruiting - Colorectal Cancer Clinical Trials

Integrative Omics Analysis for Colorectal Cancer and Metastasis

Start date: August 1, 2022
Study type: Observational [Patient Registry]

The pathogenesis of Colorectal cancer (CRC) metastasis remains unclear.We collect clinical data from our center and use Integrative omics to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.

NCT ID: NCT05468593 Recruiting - Colorectal Cancer Clinical Trials

Patient Outcomes After Hepatic Artery Infusion Pump Placement

Start date: July 12, 2022
Study type: Observational

The purpose of this study is to evaluate the surgical outcomes and the quality of life (QOL) in patients undergoing hepatic artery infusion pump placement for colorectal liver metastases (CRLM).

NCT ID: NCT05464030 Recruiting - Colorectal Cancer Clinical Trials

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Start date: July 15, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. Study details include: - Study Duration per participant: Approximately 4 months - M9140 is not available through an expanded access program

NCT ID: NCT05453825 Recruiting - Colorectal Cancer Clinical Trials

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

Start date: July 30, 2022
Phase: Phase 2
Study type: Interventional

This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: - Cohort A: CRC - Cohort B: Gastric and GEJ cancer - Cohort C: TNBC - Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)

NCT ID: NCT05453630 Recruiting - Colorectal Cancer Clinical Trials

Colonoscopy Outreach for Rural Communities Aim 2

Start date: June 16, 2022
Phase: N/A
Study type: Interventional

This study aims to test the effectiveness of a patient navigation program for increasing colonoscopy completion for colorectal cancer screening, among rural populations. The study will partner with geographically disparate primary care organizations to recruit patients aged 45-75 to the study. The patient navigation program will be delivered through a community organization. This project is critical in advancing our knowledge of the effectiveness of patient navigation for increasing colonoscopy in this patient population as well as for understanding factors that can support long term implementation and sustainability of effective interventions.

NCT ID: NCT05451849 Recruiting - Colorectal Cancer Clinical Trials

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Start date: June 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.

NCT ID: NCT05445570 Recruiting - Colorectal Cancer Clinical Trials

Non-invasive Identification of Colorectal Cancer and Adenomas in Early Stages

Start date: May 13, 2022
Study type: Observational

The NICE study is a prospective, multi-site study to train and validate a blood-based, glycoproteomic test for the early detection of advanced adenoma and colorectal cancer by collecting blood samples and associated relevant clinical information from average-risk participants who undergo routine screening colonoscopy as well as participants undergoing colonoscopy for surveillance or diagnostic indications

NCT ID: NCT05444491 Recruiting - Colorectal Cancer Clinical Trials

Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer

Start date: June 20, 2022
Study type: Observational

This study dynamically monitored the prognosis of stage I-IV colorectal cancer patients who could receive radical surgical resection by detecting the levels of polygene methylation in plasma samples from patients with colorectal cancer. In patients with colorectal cancer feasible radical surgery, plasma ctDNA methylation detection was performed before and after surgical treatment and during regular follow-up to explore the predictive effect of plasma ctDNA methylation status at different time points on postoperative recurrence. To explore whether postoperative dynamic monitoring of plasma ctDNA methylation can be used for adjuvant chemotherapy efficacy evaluation and whether it can indicate tumor recurrence and metastasis earlier than imaging examination.